

**5A\_TARGETS\_GROUP1, WIERENGA\_STAT5A\_TARGETS\_GROUP1**

HOLLERN\_EMT\_BREAST\_TUMOR\_UP, HOLLERN\_EMT\_BREAST\_TUMOR\_UP

MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_ICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP

MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP

QI\_HYPOXIA, QI\_HYPOXIA

YAO\_HOXA10\_TARGETS\_VIA\_PROGESTERONE\_UP, YAO\_HOXA10\_TARGETS\_VIA\_PROGESTERONE\_UP

GENTILE\_UV\_LOW\_DOSE\_DN, GENTILE\_UV\_LOW\_DOSE\_DN

GAUSSMANN\_MLL\_AF4\_FUSION\_TARGETS\_E\_DN, GAUSSMANN\_MLL\_AF4\_FUSION\_TARGETS\_E\_DN

MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP

REACTOME\_ATTENUATION\_PHASE, REACTOME\_ATTENUATION\_PHASE

YU\_MYC\_TARGETS\_DN, YU\_MYC\_TARGETS\_DN